Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1Terminated 1Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Multiple Myeloma 32Recurrence 8Neoplasms 6Neoplasms, Plasma Cell 5Waldenstrom Macroglobulinemia 2Immunoglobulin Light-chain Amyloidosis 2Hematologic Diseases 2Smoldering Multiple Myeloma 1Sarcoma 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Lymphoproliferative Disorders 1Lymphoma, Non-Hodgkin 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphoma 1Lymphatic Diseases 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, B-Cell 1Leukemia 1Carcinoma, Small Cell 1Blood Protein Disorders 1Amyloidosis 1

Interventions

ricolinostat 1pomalidomide 1Dexamethasone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Blood Protein Disorders × pomalidomide × Clear all
NCT01997840 2025-03-04

ACY-1215 (Ricolinostat) in Combination With Pomalidomide and Low-dose Dex in Relapsed-and-Refractory Multiple Myeloma

Celgene

Phase 1/2 Terminated
103 enrolled 21 charts
Plasma cell

Blood Protein Disorders, Hematologic Diseases, Multiple Myeloma, Neoplasms, Neoplasms by Histologic Type, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡